Ravi Dave, MD
Cardiovascular Disease · Santa Monica, CANPI 1871519934
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $57,924 of the $81,079 with a category attached, or 71.4%. It is spread thinly across 20 manufacturers, the largest accounting for just 23.6%. Reporting peaked in 2023 at $39,644 and has fallen 80.1% since, to $7,883 in 2025. Among cardiovascular disease clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 208 payments — averaging $389.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Philips North America LLC$19K
- Edwards Lifesciences$16K
- Siemens Medical Solutions USA, Inc.$11K
- GE HealthCare$10K
- Shockwave Medical, Inc$9K
- Medtronic$7K
- plus $8K from 14 others
Across 37 payments — averaging $1322.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$49K
What the payments were for
- Consulting fees$1,1001%
- Speaking & faculty fees$6,6008%
- Grants$7,0009%
- Travel & lodging$57,92471%
- Food & beverage$8,17810%
- Education$2770%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Philips North America LLC | 11 | $19,143 |
| Edwards Lifesciences | 8 | $16,413 |
| Siemens Medical Solutions USA, Inc. | 20 | $10,727 |
| GE HealthCare | 1 | $9,925 |
| Shockwave Medical, Inc | 23 | $9,128 |
| Medtronic | 7 | $7,337 |
| Abbott | 111 | $5,446 |
| Amgen | 2 | $1,100 |
| Boston Scientific | 8 | $795 |
| Heartflow, Inc. | 2 | $283 |
| Penumbra, Inc. | 1 | $235 |
| Abiomed | 2 | $191 |
| Johnson & Johnson | 2 | $150 |
| Cardiovascular Systems Inc. | 3 | $68 |
| Biotronik Inc. | 2 | $48 |
| Chiesi USA, Inc. | 1 | $28 |
| Novartis | 1 | $21 |
| Bsn Medical Inc | 1 | $21 |
| Pfizer | 1 | $13 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IGT Systems Und$18,656
- Edwards SAPIEN 3 Transcatheter Heart Valve$15,997
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$8,633
- Xience V coronary stent system$1,416
- NAEOTOM Alpha$1,366
- Artis icono floor$1,245
- Repatha$1,100
- syngo dynamics$1,097
- Optis Coronary Imaging System$757
- ARTIS icono biplane$707
- COROFLOW$329
- Dragonfly OCT$313
- GENERAL - STENTS$263
- DRAGONFLY OPSTAR$255
- Indigo System$235
- FFRct$225
- Artis pheno$187
- SAPIEN 3 Ultra RESILIA$180
- GENERAL - THERAPIES$175
- Vascular Lithotripsy$173
How this compares
$81,079 in reported general payments places this provider in the 95th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 84 | $119,713 |
| Repatha SureclickEvolocumab | 59 | $52,227 |
| XareltoRivaroxaban | 20 | $26,671 |
| Repatha SyringeEvolocumab | 12 | $17,303 |
| Praluent PenAlirocumab | 17 | $11,099 |
| Atorvastatin Calcium | 224 | $2,474 |
| Valsartan | 65 | $2,170 |
| Rosuvastatin Calcium | 84 | $1,726 |
| Metoprolol Succinate | 89 | $1,175 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 21 | $922 |
| Losartan Potassium | 87 | $911 |
| Ezetimibe | 38 | $880 |
| ClopidogrelClopidogrel Bisulfate | 103 | $862 |
| Carvedilol | 66 | $843 |
| Metoprolol Tartrate | 77 | $773 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $13 | $119,71384 claims |
| Johnson & JohnsonXarelto | $150 | $26,67120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Santa Monica
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
- Matthew BudoffTorrance$3.6M
- Eric Topolla Jolla$2.2M
- Cathleen Bairey-MerzLos Angeles$1.2M
- Gagan SinghSacramento$1.2M
- Pam Taubla Jolla$1.2M
- Wilber SuStanford$1.1M
- Thomas SmithSacramento$942K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.